Investor Presentaiton

SELECT TRIALS - VERZENIO Study Indication* Title Phase Patients Primary Outcome* ** Lilly Primary Completion Completion NCT031559971 Breast Cancer Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) 3 5637 Invasive Disease-Free Survival (IDFS) Mar 2020 May 2029 NCT05169567 Breast Neoplasm Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMonarch) 3 350 Progression-Free Survival (PFS) Nov 2023 Feb 2026 NCT03706365 Prostate Cancer NCT05288166 Prostatic |Neoplasms A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer (CYCLONE 2) A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) (CYCLONE 3) 1 Also lists NSABP Foundation Inc * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use 2|3 350 Radiographic Progression-Free Survival (rPFS) Nov 2023 Jun 2026 3 900 Radiographic Progression-Free Survival (rPFS) Assessed by Investigator Oct 2025 Oct 2027 Source: clinicaltrials.gov, July 14, 2023 2023 Q2 EARNINGS 50

View entire presentation